The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort

Breast Cancer Research and Treatment

Volumn 126, Issue 3, 2011, Pages 797-802

  Ademuyiwa, Foluso O ^a   Miller, Austin ^a   O'Connor, Tracey ^a   Edge, Stephen B ^a   Thorat, Mangesh A ^b   Sledge, George W ^c   Levine, Ellis ^a   Badve, Sunil ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adjuvant chemotherapy; Breast cancer; Oncotype DX

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADJUVANT ONLINE; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER GRADING; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NOTTINGHAM PROGNOSTIC INDEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTORS, ESTROGEN; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 79958755732     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1329-6     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106-130
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717
3. Network NCC: Breast Cancer. In: NCCN Clinical Practice Guidelines in Oncology. vol. 2010; 2010
4. Henry LR, Stojadinovic A, Swain SM, Prindiville S, Cordes R, Soballe PW (2009) The influence of a gene expression profile on breast cancer decisions. J Surg Oncol 99(6):319-323
5. Oratz R, Paul D, Cohn AL, Sedlacek SM (2007) Impact of a commercial reference laboratory test recurrence score on decision making in early stage breast cancer. J Oncol Pract 3(4):182-186 (Pubitemid 351593669)
6. Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI (2008) Does oncotype DX recurrence score affect the management of patients with early stage breast cancer? Am J Surg 196(4):527-529
7. Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, Chew HK, Gaynor ER, Hayes DF, Epstein A et al (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28(10):1671-1676
8. Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Perez EA et al. (2007) How well do standard prognostic criteria predict oncotype DX (ODX) scores? In: Proceedings of the American society of clinical oncology, vol 25. Journal of Clinical Oncology, Chicago
9. Liang H, Brufsky AM, Lembersky BB, Rastogi P, Vogel VG (2007) A retrospective analysis of the impact of oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center. In: San Antonio Breast Cancer Symposium. American Association for Cancer Research, San Antonio
10. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817-2826 (Pubitemid 40051905)
11. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403-410
12. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19(4):980-991 (Pubitemid 32176272)
13. Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP, Blamey RW, Haybittle JL (1987) Confirmation of a prognostic index in primary breast cancer. Br J Cancer 56(4):489-492 (Pubitemid 17146357)
14. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J (2010) Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health 13(4):381-387
15. Lyman GH, Cosler LE, Kuderer NM, Hornberger J (2007) Impact of a 21-gene RT-PCR assay on treatment decisions in early stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109(6):1011-1018 (Pubitemid 46435378)
16. Hornberger J, Cosler LE, Lyman GH (2005) Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early stage breast cancer. Am J Manag Care 11(5):313-324 (Pubitemid 40646936)
17. Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL (2005) The cost of adjuvant chemotherapy in patients with early stage breast carcinoma. Cancer 104(10):2054-2062 (Pubitemid 41579950)
18. Chung M, Chang HR, Bland KI, Wanebo HJ (1996) Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 77(1):97-103 (Pubitemid 26002742)
19. Dirier A, Burhanedtin-Zincircioglu S, Karadayi B, Isikdogan A, Aksu R (2009) Characteristics and prognosis of breast cancer in younger women. J BUON 14(4):619-623
20. Gajdos C, Tartter PI, Bleiweiss IJ, Bodian C, Brower ST (2000) Stage 0 to stage III breast cancer in young women. J Am Coll Surg 190(5):523-529 (Pubitemid 30230699)